Abstract
A large percentage of patients with cancer will develop brain metastases, and many of them will die within a few months following diagnosis of intracranial metastasis. Although the majority of the central nervous system metastases are derived from a well-known primary neoplasm, about 5-10% of brain metastases are from an unknown source, making the tissue diagnosis a first step in the search for a primary malignancy. The pathologist utilizes several immunohistochemical and molecular diagnostic tools for such investigation, helping the clinical oncologist to narrow down the clinical and radiologic exploration. Recently, analysis of actionable biomarkers for target therapy in brain metastasis has become significant due to reports of discrepancy of potential biomarkers between primary tumors and metastatic brain deposits.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
